TACSTD2 and adenocarcinoma: Interestingly, in neuroendocrine subtypes of lung cancer, high TROP expression is associated with lower patient mortality when compared to non-endocrine subtypes of lung cancer, such as adenocarcinoma or squamous, even if these subtypes are also expressing high levels of TROP2.10 This suggests a differential role for TROP2 in neuroendocrine subtypes.